Skip to main content
Back
Watch Compare

Cue Biopharma, Inc.

Data quality: 100%
CUE
Nasdaq Manufacturing Chemicals
$0.50
▲ $0.21 (71.36%)
Mkt Cap: 27.88 M
Price
$0.29
Mkt Cap
27.88 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Revenue grew 16.44% annually over 5 years — strong growth
Negative free cash flow of -21.86 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 179.31%
Capital efficient — spends only 0.64% of revenue on capex

Growth

Revenue Growth (5Y)
16.44%
Above sector avg (1.82%)
Revenue (1Y)195.75%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-169.41%
Below sector avg (-53.47%)
ROIC-111.66%
Net Margin-96.85%
Op. Margin-96.67%

Safety

Debt / Equity
N/A
Current Ratio1.66
Interest Coverage-265.52

Valuation

PE (TTM)
-1.05
Above sector avg (-1.48)
P/B Ratio2.10
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -1.1 -1.5
P/B 2.1 1.6
ROE % -169.4 -53.5
Net Margin % -96.9 -41.5
Rev Growth 5Y % 16.4 1.8
D/E — 0.3

Analyst Price Target

1 analyst
Buy
Current
$0.50
+697.0%
Target
$4.00
$4.00
$4.00
$4.00
Forecast
Forward EPS -$0.60
Est. Revenue 1.00 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 -$0.60
-$0.60 – -$0.60
 1.00 M 1
FY2026 -$0.58
-$0.58 – -$0.58
 1.00 M 1

Earnings Surprises

Last 4 quarters
Quarter Est. EPS Actual EPS Surprise
Q42025 -$0.09 $0.01 +111.1%
Q32025 -$0.09 -$0.07 +17.7%
Q22025 -$0.13 -$0.09 +30.8%
Q12025 -$0.15 -$0.17 -10.9%

All Fundamental Metrics
Growth
Revenue Growth (1Y) 195.75% Revenue Growth (3Y) 123.67%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 16.44% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 27.47 M Net Income (TTM) -26.60 M
ROE -169.41% ROA -73.54%
Gross Margin N/A Operating Margin -96.67%
Net Margin -96.85% Free Cash Flow (TTM) -21.86 M
ROIC -111.66% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1.66
Interest Coverage -265.52 Asset Turnover 0.76
Working Capital 10.30 M Tangible Book Value 13.25 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1.05 Forward P/E N/A
P/B Ratio 2.10 P/S Ratio 1.02
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -78.42%
Market Cap 27.88 M Enterprise Value 16.18 M
Per Share
EPS (Diluted TTM) -0.28 Revenue / Share 0.28
FCF / Share -0.22 OCF / Share -0.22
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0.64% FCF Conversion 82.19%
SBC-Adj. FCF -27.58 M Growth Momentum 179.31

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 27.47 M 9.29 M 5.49 M 1.25 M 14.94 M
Net Income -26.60 M -40.67 M -50.73 M -53.01 M -44.16 M
EPS (Diluted) -0.28 -0.72 -1.11 -1.49 —
Gross Profit — — — — —
Operating Income -26.55 M -41.50 M -52.15 M -53.22 M -43.71 M
EBITDA — — — — —
R&D Expenses 37.74 M 36.30 M 40.80 M 38.58 M 41.35 M
SG&A Expenses — — — — —
D&A 958,000.0 397,000.0 556,000.0 922,216.0 1.26 M
Interest Expense 100,000.0 100,000.0 130,000.0 -713,815.0 —
Income Tax 500,000.0 400,000.0 — 0.0 495,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 42.21 M 32.19 M 61.53 M 91.28 M 83.40 M
Total Liabilities 15.78 M 14.69 M 24.45 M 25.60 M 17.91 M
Shareholders' Equity 26.43 M 17.50 M 37.09 M 65.68 M 65.49 M
Total Debt — 37,000.0 4.04 M 8.07 M —
Cash & Equivalents 27.14 M 22.46 M 48.51 M 51.61 M 64.37 M
Current Assets 36.98 M 25.14 M 51.45 M 77.19 M 68.47 M
Current Liabilities 13.49 M 13.69 M 17.08 M 11.55 M 12.79 M